A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2012
At a glance
- Drugs TV 5010 (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 14 Nov 2012 New trial record